Antagonistic actions of PAK1 and NF2 /Merlin drive myelin membrane expansion in oligodendrocytes
Glia · 2024
DOI: 10.1002/glia.24570 ↗Kurz gefasst
Fachartikel in der Zeitschrift Glia, 2024. Verfasst von Lucas Baudouin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, Institut du Cerveau, Paris Brain Institute - ICM, Inserm, CNRS, APHP, Hôpital de la Pitié-Salpêtrière, Paris, France. Hauptthemen laut MEDLINE: p21-Activated Kinases, Oligodendroglia, Myelin Sheath. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NEURATRIS, Fondation Marie-Ange Bouvet-Labruyère, Fondation pour l'Aide à la Recherche sur la Sclérose en Plaques.
Abstract (Originalsprache)
In the central nervous system, the formation of myelin by oligodendrocytes (OLs) relies on the switch from the polymerization of the actin cytoskeleton to its depolymerization. The molecular mechanisms that trigger this switch have yet to be elucidated. Here, we identified P21‐activated kinase 1 (PAK1) as a major regulator of actin depolymerization in OLs. Our results demonstrate that PAK1 accumulates in OLs in a kinase‐inhibited form, triggering actin disassembly and, consequently, myelin membrane expansion. Remarkably, proteomic analysis of PAK1 binding partners enabled the identification of NF2/Merlin as its endogenous inhibitor. Our findings indicate that Nf2 knockdown in OLs results in PAK1 activation, actin polymerization, and a reduction in OL myelin membrane expansion. This effect is rescued by treatment with a PAK1 inhibitor. We also provide evidence that the specific Pak1 loss‐of‐function in oligodendroglia stimulates the thickening of myelin sheaths in vivo . Overall, our data indicate that the antagonistic actions of PAK1 and NF2/Merlin on the actin cytoskeleton of the OLs are critical for proper myelin formation. These findings have broad mechanistic and therapeutic implications in demyelinating diseases and neurodevelopmental disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sorbonne Université, Institut du Cerveau, Paris Brain Institute - ICM, Inserm, CNRS, APHP, Hôpital de la Pitié-Salpêtrière, Paris, France.
- Al-Quds University, Faculty of Medicine, Jerusalem, Palestine.
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.
- Sorbonne Université, Inserm, UMS Production et Analyse des Données en Sciences de la vie et en Santé, PASS, Plateforme Post-génomique de la Pitié-Salpêtrière, Paris, France.
- Institut des Neurosciences Paris-Saclay, UMR 9197, CNRS, Université Paris-Saclay, Saclay, France.
ORCID-Profile: Lamia Bouslama-Oueghlani
Förderung
- NEURATRIS
- Fondation Marie-Ange Bouvet-Labruyère
- Fondation pour l'Aide à la Recherche sur la Sclérose en Plaques
- Fondation Jérôme Lejeune
- IHU-A-ICM
- Carnot Maturation
Zitieren
APA
Baudouin, L., Adès, N., Kanté, K., Bachelin, C., Hmidan, H., Deboux, C., Panic, R., Ben Messaoud, R., Velut, Y., Hamada, S., Pionneau, C., Duarte, K., Poëa-Guyon, S., Barnier, J. V., Nait Oumesmar, B., & Bouslama-Oueghlani, L. (2024). Antagonistic actions of PAK1 and NF2 /Merlin drive myelin membrane expansion in oligodendrocytes. Glia. https://doi.org/10.1002/glia.24570
Vancouver
Baudouin L, Adès N, Kanté K, Bachelin C, Hmidan H, Deboux C, et al. Antagonistic actions of PAK1 and NF2 /Merlin drive myelin membrane expansion in oligodendrocytes. Glia. 2024. doi:10.1002/glia.24570
BibTeX
@article{Baudouin2024,
author = {Baudouin, Lucas and Adès, Noémie and Kanté, Kadia and Bachelin, Corinne and Hmidan, Hatem and Deboux, Cyrille and Panic, Radmila and Ben Messaoud, Rémy and Velut, Yoan and Hamada, Soumia and Pionneau, Cédric and Duarte, Kévin and Poëa-Guyon, Sandrine and Barnier, Jean-Vianney and Nait Oumesmar, Brahim and Bouslama-Oueghlani, Lamia},
title = {Antagonistic actions of PAK1 and NF2 /Merlin drive myelin membrane expansion in oligodendrocytes},
journal = {Glia},
year = {2024},
doi = {10.1002/glia.24570}
}
EUVIMED